Analyst Price Target is C$0.96
▲ +336.36% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Hemostemix in the last 3 months. The average price target is C$0.96, with a high forecast of C$0.96 and a low forecast of C$0.96. The average price target represents a 336.36% upside from the last price of C$0.22.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Hemostemix.
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Read More